CorEvitas — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness RegistryThe design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Approximately 1,500 myasthenia gravis subjects with no defined upper limit and 50 clinical neurology sites will be recruited.	Myasthénie	À vérifier	À vérifier	United States	À vérifier
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness RegistryThe design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Approximately 1,500 myasthenia gravis subjects with no defined upper limit and 50 clinical neurology sites will be recruited.	Myasthénie	À vérifier	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry	Myasthénie	À vérifier	NCT07217509	PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry	ENROLLING_BY_INVITATION

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.